Karen Noblett - Jan 31, 2024 Form 4 Insider Report for Axonics, Inc. (AXNX)

Role
Chief Medical Officer
Signature
Kari L. Keese, as Attorney-in-fact for Karen Noblett
Stock symbol
AXNX
Transactions as of
Jan 31, 2024
Transactions value $
-$764,603
Form type
4
Date filed
2/2/2024, 05:59 PM
Previous filing
Jan 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXNX Common Stock Options Exercise $0 +27.5K +150.97% $0.00 45.7K Jan 31, 2024 Direct
transaction AXNX Common Stock Sale -$765K -11.3K -24.69% $67.74 34.4K Jan 31, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXNX Performance-Based Restricted Stock Units Options Exercise $0 -6.5K -100% $0.00* 0 Jan 31, 2024 Common Stock 6.5K Direct F3
transaction AXNX Performance-Based Restricted Stock Units Options Exercise $0 -15K -100% $0.00* 0 Jan 31, 2024 Common Stock 15K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the vesting of Performance-Based Restricted Stock Units disclosed herein and the vesting of Restricted Stock Awards.
F2 This transaction was executed in multiple trades at prices ranging from $67.53 to $68.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024.
F4 Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.